Skip to main content
Fig. 2 | Pediatric Rheumatology

Fig. 2

From: Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review

Fig. 2

Clinical course and treatment. Clinical course and treatment of the patient. MPT, methylprednisolone pulse therapy; PSL, prednisolone; Lipo-Dex, liposteroid dexamethasone; IVCY, intravenous cyclophosphamide; CyA, cyclosporine A; Tac, tacrolimus; MMF, mycophenolate mofetil; IVIG, intravenous immunoglobulin; PE, plasma exchange; RTX, rituximab; HFNC, High-flow nasal cannula; CMV, conventional mechanical ventilation; VV-ECMO, veno-venous extracorporeal membrane oxygenation; KL–6, Krebs von den Lungen-6; MDA5, melanoma differentiation-association gene 5; P/F ratio, PaO2/FiO2 ratio

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096